SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

CAVAZZA PAOLO

(Last)

(First)

(Middle)

VIA TESSERETE, 10

(Street)

LUGANO

00000

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
11/18/2004

3. Issuer Name and Ticker or Trading Symbol
SCICLONE PHARMACEUTICALS INC [ SCLN ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	457,815	D
Common Stock	481,069	I	I⁽¹⁾
Common Stock	2,500	I	I⁽²⁾
Common Stock	2,927,372	I	I⁽³⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Call Options (right to buy)	⁽⁶⁾	03/18/2005	Common Stock	40,000	$5	D
Call Options (right to buy)	⁽⁶⁾	06/17/2005	Common Stock	215,000	$5	I	I⁽⁴⁾
Call Options (right to buy)	⁽⁶⁾	06/17/2005	Common Stock	150,000	$2.5	I	I⁽⁴⁾
Call Options (right to buy)	⁽⁶⁾	03/18/2005	Common Stock	278,000	$5	I	I⁽⁴⁾
Put Options (obligation to buy)	⁽⁶⁾	03/18/2005	Common Stock	100,000	$5	D
Put Options (obligation to buy)	⁽⁶⁾	03/18/2005	Common Stock	15,000	$7.5	D
Put Options (obligation to buy)	⁽⁶⁾	03/18/2005	Common Stock	537,000	$5	I	I⁽⁵⁾
Put Options (obligation to buy)	⁽⁶⁾	06/17/2005	Common Stock	550,000	$5	I	I⁽⁵⁾

Explanation of Responses:

1. Shares directly owned by Aptafin S.p.A. ("Aptafin"), which is owned by Paolo and members of his family.

2. Shares directly owned by Chaumiere Consultadoria e Servicos S.A. ("Chaumiere"), which is an indirect wholly-owned subsidiary of Aptafin.

3. Shares directly owned by Defiante Farmaceutica, L.D.A. ("Defiante"). Defiante is 58% directly owned by Sigma Tau Finanzaria S.p.A. ("Sigma Tau") and 42% directly owned by Sima Tau's wholly-owned subsidiary, Sigma-Tau International S.A. Paolo Cavazza directly and indirectly owns 40% of Sigma Tau.

4. Call options directly owned by Defiante.

5. Direct obligations of Defiante.

6. Immediately.

	/s/ Paolo Cavazza	01/20/2005
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.